Deutsche Bank’s Actuate Therapeutics ACTU Stock Holding History

Deutsche Bank’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99.7K	Buy	36,398 +27,089	+291%	+$112K	﹤0.01%	3282
2025 Q4	$57K	Buy	9,309 +8,051	+640%	+$55.3K	﹤0.01%	3430
2025 Q3	$8.42K	Sell	1,258 -9,181	-88%	-$66.6K	﹤0.01%	3525
2025 Q2	$63.8K	Buy	+10,439	New	+$91.2K	﹤0.01%	3381

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

PVM

Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank's ACTU Position: Q1 2026 in Review

Deutsche Bank increased its Actuate Therapeutics (ACTU) stake by 291% in Q1 2026, buying an estimated $112K and bringing the position to 36,398 shares worth $99.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

Deutsche Bank first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

Deutsche Bank held 36,398 shares of Actuate Therapeutics worth $99.7K as of Q1 2026.
Deutsche Bank bought 27,089 Actuate Therapeutics shares in Q1 2026, an estimated $112K.
Actuate Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3282 holding.
Deutsche Bank first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.